Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$28.66 USD
-0.96 (-3.24%)
Updated May 23, 2024 12:28 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
[RNA]
Reports for Purchase
Showing records 21 - 40 ( 62 total )
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Preview: RNA to Present Further Promising Drisapersen Analyses at AAN - Recent FDA Comments Signal Greater Receptiveness in DMD - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Preview: RNA to Present Further Promising Drisapersen Analyses at AAN - Recent FDA Comments Signal Greater Receptiveness in DMD - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Preview: RNA to Present Further Promising Drisapersen Analyses at AAN - Recent FDA Comments Signal Greater Receptiveness in DMD - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Q4 Update - Demand V Results Misunderstood - Duration of Response Supports Drisapersen''s Efficacy - Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM and Increasing Price Target to $12; Drisapersen Data Highlights Opportunity with Long- Term Dosing and Validates Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Phase III Post-hoc Analysis Promising - Support Potential for Optimized Pipeline Compounds - Awaiting Further Clarity on Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Phase III Post-hoc Analysis Promising - Support Potential for Optimized Pipeline Compounds - Awaiting Further Clarity on Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Regains Drisapersen Rights - Further Analysis Pending RNA''s Receipt of Data and to Inform Potentially More Potent Pipeline - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L